JP2020502259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502259A5 JP2020502259A5 JP2019545897A JP2019545897A JP2020502259A5 JP 2020502259 A5 JP2020502259 A5 JP 2020502259A5 JP 2019545897 A JP2019545897 A JP 2019545897A JP 2019545897 A JP2019545897 A JP 2019545897A JP 2020502259 A5 JP2020502259 A5 JP 2020502259A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- alkyl
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229940080328 Arginase inhibitor Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 238000009169 immunotherapy Methods 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 102000004452 Arginase Human genes 0.000 claims 1
- 108700024123 Arginases Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 150000001638 boron Chemical class 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419250P | 2016-11-08 | 2016-11-08 | |
| US62/419,250 | 2016-11-08 | ||
| US201762559931P | 2017-09-18 | 2017-09-18 | |
| US62/559,931 | 2017-09-18 | ||
| PCT/US2017/060636 WO2018089490A1 (en) | 2016-11-08 | 2017-11-08 | Arginase inhibitor combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502259A JP2020502259A (ja) | 2020-01-23 |
| JP2020502259A5 true JP2020502259A5 (https=) | 2020-12-03 |
Family
ID=60409467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545897A Pending JP2020502259A (ja) | 2016-11-08 | 2017-11-08 | アルギナーゼ阻害剤併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11291674B2 (https=) |
| EP (1) | EP3538111B1 (https=) |
| JP (1) | JP2020502259A (https=) |
| KR (1) | KR20190104521A (https=) |
| CN (1) | CN110352063A (https=) |
| AU (1) | AU2017356942A1 (https=) |
| CA (1) | CA3042878A1 (https=) |
| IL (1) | IL266534A (https=) |
| MA (1) | MA46793A (https=) |
| MX (1) | MX2019005402A (https=) |
| PH (1) | PH12019501010A1 (https=) |
| TW (1) | TW201828959A (https=) |
| WO (1) | WO2018089490A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3743510A1 (en) * | 2018-01-28 | 2020-12-02 | Universite De Geneve | Arginase suppression for cancer treatment |
| CN117186134A (zh) * | 2018-02-17 | 2023-12-08 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| AU2019229978B2 (en) | 2018-03-05 | 2024-05-30 | Arcus Biosciences, Inc. | Arginase inhibitors |
| EP3765006A4 (en) * | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| WO2019186497A1 (en) | 2018-03-29 | 2019-10-03 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| JP7208262B2 (ja) * | 2018-05-22 | 2023-01-18 | イミュニティーバイオ インコーポレイテッド | ポロキサマーを用いてｎｋ－９２細胞増殖を最適化する方法 |
| MA53427B1 (fr) * | 2018-08-22 | 2024-06-28 | Astrazeneca Ab | Inhibiteurs de l'arginase et leurs méthodes d'utilisation |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI828800B (zh) * | 2018-11-16 | 2024-01-11 | 美商阿克思生物科學有限公司 | Arg1及/或arg2之抑制劑 |
| WO2020160707A1 (en) * | 2019-02-06 | 2020-08-13 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Alkylboronic acids as arginase inhibitors |
| CN114599372A (zh) * | 2019-11-04 | 2022-06-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| CN111138358B (zh) * | 2019-12-17 | 2023-04-18 | 中国药科大学 | Usp8抑制剂及其制备方法与应用 |
| EP4251280A4 (en) * | 2020-11-30 | 2024-11-06 | Merck Sharp & Dohme LLC | ARGINASE 1 BINDERS TO INHIBIT ARGINASE 1 ACTIVITY |
| EP4251202A4 (en) * | 2020-11-30 | 2025-04-09 | Merck Sharp & Dohme LLC | ARGINASE-1 BINDING AGENT FOR INHIBITING ARGINASE-1 ACTIVITY |
| TW202241469A (zh) * | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| WO2022215840A1 (ko) * | 2021-04-06 | 2022-10-13 | (주)에스엠티바이오 | 간외 담도암의 예방 또는 치료용 조성물 |
| EP4337092A1 (en) * | 2021-05-13 | 2024-03-20 | Ventana Medical Systems, Inc. | Real-time prediction of tissue fixation time |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| DE69839355T2 (de) | 1997-07-29 | 2009-06-04 | Alcon Laboratories, Inc., Fort Worth | Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat |
| AU9797998A (en) | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| CA2415174A1 (en) | 2000-07-06 | 2002-01-17 | Thomas W. Bell | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) * | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| WO2007005620A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Arginase ii: a target treatment of aging heart and heart failure |
| LT2389352T (lt) | 2009-01-26 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Arginazės inhibitoriai ir naudojimo būdai |
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| HRP20160305T1 (hr) | 2010-10-26 | 2016-07-01 | Mars, Incorporated | Borati kao inhibitori arginaze |
| CA2824599C (en) | 2010-12-31 | 2020-03-10 | Astrazeneca Uk Limited | Arginase inhibitors and methods of use thereof |
| WO2013059437A1 (en) | 2011-10-19 | 2013-04-25 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| JP6073343B2 (ja) | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| CN104540836B (zh) | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
| EA201690746A1 (ru) | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| CN107405404A (zh) | 2015-03-20 | 2017-11-28 | 塞米·欧尤·奥皮约 | 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途 |
| US10143699B2 (en) | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| SG11201802961PA (en) * | 2015-10-30 | 2018-05-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
-
2017
- 2017-11-08 JP JP2019545897A patent/JP2020502259A/ja active Pending
- 2017-11-08 CA CA3042878A patent/CA3042878A1/en not_active Abandoned
- 2017-11-08 TW TW106138689A patent/TW201828959A/zh unknown
- 2017-11-08 CN CN201780076069.4A patent/CN110352063A/zh active Pending
- 2017-11-08 EP EP17801266.2A patent/EP3538111B1/en active Active
- 2017-11-08 MA MA046793A patent/MA46793A/fr unknown
- 2017-11-08 US US15/807,357 patent/US11291674B2/en active Active
- 2017-11-08 AU AU2017356942A patent/AU2017356942A1/en not_active Abandoned
- 2017-11-08 WO PCT/US2017/060636 patent/WO2018089490A1/en not_active Ceased
- 2017-11-08 MX MX2019005402A patent/MX2019005402A/es unknown
- 2017-11-08 KR KR1020197016533A patent/KR20190104521A/ko not_active Withdrawn
-
2019
- 2019-05-07 PH PH12019501010A patent/PH12019501010A1/en unknown
- 2019-05-08 IL IL266534A patent/IL266534A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502259A5 (https=) | ||
| JP6956967B2 (ja) | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 | |
| JP2018521135A5 (https=) | ||
| JP2018507197A5 (https=) | ||
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CN107801379A (zh) | 抗癌剂 | |
| JP6240083B2 (ja) | 樹状細胞癌ワクチンのための小分子エンハンサー | |
| US20240065987A1 (en) | Anti-cancer activity of adamantane derivatives | |
| JPWO2016104657A1 (ja) | 癌治療剤 | |
| TWI829329B (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| EP3922251B1 (en) | Cancer immunotheraphy adjuvant | |
| Marabelle et al. | Radiotherapy and toll-like receptor agonists | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| WO2019076269A1 (zh) | 甲羟戊酸通路抑制剂及其药物组合物 | |
| JP2020531495A5 (https=) | ||
| US11559504B2 (en) | Ceramide nanoliposomes, compositions and methods of using for immunotherapy | |
| CN110891944A (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| Cornel et al. | P09. 02 Epigenetic modulation of neuroblastoma enhances T-and NK cell immunogenicity via induction of surface expression of MHC class I and MICA/MICB | |
| Wang et al. | Combined use of TLR4 and TLR7/8 agonists to improve the efficacy of immune checkpoint inhibitors in “hot” tumor treatment and the establishment of long-term immune protection | |
| Vankayalapati et al. | 870 Targeting GCN2 kinase-driven stress response inactivation to restore tumor immunity in metastatic triple negative breast cancer | |
| RU2021106915A (ru) | Комбинированная терапия злокачественной опухоли с использованием производного хинолинкарбоксамида | |
| Hwu et al. | Effective Innate and Adaptive Antimelanoma | |
| HK1250213B (en) | Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide |